Introduction {#s0005}
============

The effect of cataracts on vision is often described as being similar to looking through a waterfall or a piece of waxed paper. Poor vision from cataracts affects 80% of people aged ≥75 years.[@bib1] This disease causes clouding of the eye lens, which reduces the amount of incoming light and deteriorates vision. Daily functions such as reading or driving a car may become difficult or impossible.[@bib2]Thus, patients may require frequent change in eyeglass prescriptions.[@bib3] It is estimated that 200 million people have cataracts worldwide.[@bib4; @bib5] Data from the National Institutes of Health indicate that \>350,000 cataract surgeries are performed annually in the United States.

The lens is the clear part of the eye that helps to focus light and images on the retina.[@bib6] The retina is the light-sensitive tissue at the back of the eye. In a normal eye, light passes through the transparent lens to the retina. Once it reaches the retina, light is changed into nerve signals that are sent to the brain.[@bib7] The lens must be clear for the retina to receive a sharp image. If the lens is cloudy as a result of cataracts, the image will be blurred. The lens is mostly made of water and protein. The proteins are arranged to let light pass through and focus on the retina. Sometimes, some lens proteins clump together and begin to cloud a small area of the lens. Over time, the cells accumulate and cause the lens to cloud, thereby resulting in blurred or fuzzy images.[@bib4; @bib8] Cataracts are the leading cause of visual loss among adults \>55 years old. Cataract surgery costs Medicare more money than any other medical procedure, with 60% of those who initially qualify for Medicare already having cataracts.[@bib9] Most people are concerned regarding the time of onset of cataracts and not about its occurrence. Hence, preventative steps at an early stage in life may lead to good eye health and prevent cataracts.[@bib10] Many factors influence vision and cataract development, for example, age, nutrition, heredity, medications, toxins, health habits, sunlight exposure, and head trauma. Cataracts can also be caused by high blood pressure, kidney disease, diabetes, or direct trauma to the eye.[@bib11; @bib12] Although cataract surgeries have advanced progressively, cataracts are still the leading cause of blindness and are a profound economic cost to society.[@bib13; @bib14; @bib15] In this study, we used 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) to identify the proteins that change during the formation of lens opacity and liquid chromatographic tandem mass spectrometry (LC/MS/MS) to evaluate post-translation modifications of the proteins. Investigating the protein changes during various stages of cataracts elucidated the mechanism of the formation of cataracts and might be helpful in designing new therapies.

Materials and Methods {#s0010}
=====================

Lens materials were obtained during cataract surgery. All patients in this study received serial ophthalmic examinations, including intraocular pressure (IOP), visual acuity, and retinal examination. Patients with ocular diseases other than cataracts were excluded. Patients (38 women and 42 men), aged 56 to 85 years (mean, 72 years), were followed up after 3 to 24 weeks (mean, 5 weeks). The study was performed according to the tenets of the Declaration of Helsinki for research involving human participants.

Patients with Stage 2 to 5 cataracts were enrolled in the study. The patients did not have any systemic diseases or eye diseases other than cataracts. They underwent phacoemulsification surgery using a phacoemulsification machine (Universal II; Alcon, Houston, Texas). Lens materials were collected into bags by the machine after quaking the lens into small particles by ultrasound. Lens opacity was classified according to the Lens Opacities Classification System (LOCS) before surgery.[@bib16; @bib17] This classification involves comparison of the slit lamp view of the lens to a color plate of LOCS III standards. LOCS uses standard reference photographs taken during slit lamp examination. The extent of opacification of cortical (C) and posterior subcapsular (P) changes was defined, and color changes of the nucleus as well as the intensity of nuclear opalescence was noted using LOCS. Lens opacity was scored according to the description in LOCS, for example, N0 and NIV were denoted as 0 and 4, respectively. After adding the scores of the 4 parts (nuclear color, nuclear opacity, cortical cataracts, and posterior subcapsule), a total score (0--15) was obtained. These scores were used to categorize cataracts into 5 stages: score 0, Stage 1; scores 1 to 4, Stage 2; scores 5 to 8, Stage 3; scores 9 to 12, Stage 4; and scores 13 to 15, Stage 5.

Two-dimensional Gel Electrophoresis {#s0015}
===================================

Sample Preparation and Running of Gels {#s0020}
--------------------------------------

An aliquot containing 100 μg of protein sample was diluted with 350 μL of rehydration buffer containing 8-M urea, 4% \[3-(3-cholamidopropyl)dimethylammonio\]-1- propanesulfonate\], 65-mM dithioerythritol (DTE), 0.5% ampholytes, and a trace of bromophenol blue. An immobilized pH gradient (17 cm; pH 3--10; ReadyStrip IPG strip; Bio-Rad, Tokyo, Japan) was hydrated overnight, and the samples were focused for a total of 60 kVh (PROTEAN IEF cell; Bio-Rad) at 20°C and then stored at −80°C. Strips were equilibrated with 3 mL of an equilibrium solution containing 50-mM Tris--hydrocholride (pH 8.8), 6-M urea, 30% glycerol, 2% sodium dodecyl sulfate (SDS), a trace of bromophenol blue, and DTE (1% w/v) for 20 minutes, followed by equilibration for 20 minutes in the same solution containing iodoacetamide (IAA; 2.5% w/v) instead of DTE. The strips were transferred to the tops of 12% PAGE and held in position with molten 0.5% agarose in running buffer containing 25-mM Tris, 0.192-M glycine, and 0.1% SDS. The gels were run at 16 mA for 30 minutes, followed by 50 mA for 4 to 5 hours.

Detection of Protein Spots and Data Analysis {#s0025}
--------------------------------------------

The gels were routinely stained with Coomassie blue and then scanned using a GS-800 imaging densitometer with PDQuest software (version 7.1.1; Bio-Rad). To evaluate intra- and intersample variability, the gels were analyzed as follows: protein spots from each gel were detected and matched automatically to generate a master gel image from the matched gel sets. Finally, the intensity of the spots was compared between gels. Data were exported to Microsoft Excel (Microsoft Inc, Redmond, Washington) for creating correction and spot intensity graphs.

In-Gel Digestion {#s0030}
----------------

The procedure of Terry et al[@bib18] was slightly modified and used for in-gel digestion of proteins from the Coomassie blue-stained gels for nanoscale capillary LC/MS/MS. In brief, each spot of interest on the Coomassie blue-stained gel was sliced into 1-mm cubes. The proteins in these gels were reduced and methylated with 50-mM DTE and 100-mM IAA in 50-mM ammonium bicarbonate. The gel pieces were washed 2 times with 50% v/v acetonitrile (ACN) in 100-mM ammonium bicarbonate buffer (pH 8.0) for 10 minutes at room temperature. They were then soaked in 100% ACN for 5 minutes, dried in a lyophilizer for 20 to 30 minutes, and rehydrated in 50-mM ammonium bicarbonate buffer (pH 8.0) containing 10 μg/mL trypsin (Promega, Madison, Wisconsin) until fully immersed. After incubating for 16 to 20 hours at 30°C, the remaining trypsin solution was transferred into a new microtube. The gel pieces were resuspended with 50% ACN in 5.0% formic acid (FA) for 60 minutes, and then concentrated to dryness.

Nanoelectrospray Mass Spectrometry {#s0035}
==================================

Nanoscale capillary LC/MS/MS was used to analyze the proteins involved in the development of cataracts. The Ultimate Capillary LC System (LC Packings, Amsterdam, the Netherlands) coupled to a QSTARXL quadrupole-time of flight (Q-TOF) mass spectrometer (Applied Biosystem/MDS Sciex, Foster City, California) was used for analysis. Nanoscale capillary LC separation was performed on a reverse phase C18 column (15 cm × 75 μm inner diameter) with a flow rate of 200 nL/min and a 60-minute linear gradient of 5% to 50% buffer B. Buffer A contained 0.1% FA in 5% aqueous ACN, and buffer B contained 0.1% FA in 95% aqueous ACN. The nano-LC tip for online LC/MS was a PicoTip (FS360-20-10-D-20; New Objective, Cambridge, Massachusetts). Data acquisition was performed using automatic information dependent acquisition (IDA; Applied Biosystem/MDS Sciex). Automatic IDA finds the most intense ions in TOF MS spectra and then performs optimized MS/MS analysis on these ions. The product ion spectra generated by nano-LC/MS/MS were searched against National Center for Biotechnology Information (NCBI) databases for exact matches using the ProID program (Applied Biosystem/MDS Sciex) and the MASCOT search program (MASCOT search program; Matrix Science, Inc, Boston, Massachusetts). A mammalian taxonomy restriction was used, and the mass tolerance of both precursor and fragment ions was set to ± 0.3 Da. Carbamidomethyl cysteine was set as a fixed modification, whereas phosphorylation of serine, threonine, and tyrosine, and other modifications were set as variable modifications. All identified phosphopeptides were confirmed by manual interpretation of the spectra.

Results {#s0040}
=======

Lens materials from various stages were prepared for 2D-PAGE. To identify protein expression, master gels were computed from scanned images of quartet silver-stained gels. The scanned gel images were processed using the Proteomics Software System developed by Xzillion (Frankfurt am Main, Germany). The master gel was computed by registering and jointly segmenting multiple registered replicates. Algorithmic details can be found in the SEQUEST algorithm (version C1; Thermo Fisher Scientific, Waltham, Massachusetts) incorporated into the ThermoFinnigan BIOWORKS software (version 3.0; Thermo Fisher Scientific). Spot volumes were determined by modeling optical density of individual spot segments using 2D Gaussian analysis. To correct for variability due to gel electrophoresis, quartet gels were run for each cataract stage. In addition, spots expressed in \<50% of the gels were disregarded. Furthermore, upregulation of proteins was considered significant when the corresponding spot volumes were increased by more than twofold. Representative master gels showed proteins expressed in different stages of cataracts. The proteins varied between 10 and 120 kDa in size and had isoelectric point (pI) values ranging from 5 to 9 ([Figures 1--4](#f0005 f0010 f0015 f0020){ref-type="fig"}).

No patient with Stage 1 cataracts underwent surgery; therefore, data were collected from patients with Stage 2 to 5 cataracts. Spots 1 to 44 were expressed in Stage 2 ([Figure 1](#f0005){ref-type="fig"} and [Tables I and II](#t0005 t0010){ref-type="table"}). After analysis, the major proteins in Stage 2 were crystallin βB1, αB, α A, and βA4. Eleven spots were identified as crystallin βB1. Of these, 5 were phosphorylated, 1 was acetylated, and none was truncated. In addition, 11 protein spots were identified as crystallin αB in Stage 2. Of these, 5 were phosphorylated, 1 was both phosphorylated and acetylated, and none was truncated. Eleven spots were identified as crystallin αA. Six of these were phosphorylated, 6 were acetylated, 5 were both phosphorylated and acetylated, and all were truncated. Eight spots were identified as crystallin βA4. Of these, 3 were phosphorylated and none was acetylated. However, all crystallin βA4 proteins were truncated. Among the protein spots in Stage 2, 46.3% were phosphorylated ([Tables I and II](#t0005 t0010){ref-type="table"}); the ratio of phosphorylated to nonphosphorylated proteins was 17:24 (41.46% phosphorylated proteins). Acetylated proteins were more abundant than nonacetylated ones; the ratio of acetylated to nonacetylated proteins was 8:33. Only 19.5% of crystallin proteins in Stage 2 were acetylated. The ratio of truncated to nontruncated proteins was 19:22 (46.3% truncated) ([Tables I and II](#t0005 t0010){ref-type="table"}). The proportions of phosphorylated and truncated proteins were high in Stage 2, whereas that of acetylated proteins was low.

The major proteins associated with Stage 3 ([Figure 2](#f0010){ref-type="fig"} and [Tables I and II](#t0005 t0010){ref-type="table"}) were crystallin αA, βB1, βA3, and βA4. Thirteen proteins were identified as crystallin αA, 6 of which were phosphorylated, 7 were acetylated, and 5 were both phosphorylated and acetylated. All crystallin αA proteins in Stage 3 were truncated. Ten proteins were identified as crystallin βB1. Of these, 8 were phosphorylated, 2 were acetylated, and none was truncated. Six proteins were identified as crystallin βA3. Of these, 5 were phosphorylated, 1 was acetylated, and all 6 were truncated. Six proteins in Stage 3 were identified as crystallin βA4. None of these were phosphorylated or acetylated; however, they were all truncated. In Stage 3, the ratio of phosphorylated to nonphosphorylated proteins was 19:16 (54.2% phosphorylated). The ratio of acetylation was lower than that of phosphorylation, with 10:25 (28.6%) proteins carrying acetyl groups ([Tables I and II](#t0005 t0010){ref-type="table"}). The ratio of truncated to nontruncated proteins was 25:10, indicating that more than half of the proteins in Stage 3 were truncated (71.4%; [Tables I and II](#t0005 t0010){ref-type="table"}). The phosphorylation ratio in Stage 3 was higher than that in Stage 2 (Stage 3 to Stage 2, 54.3%:46.3%). Similarly, the acetylation ratio in Stage 3 was also higher than that in Stage 2 (Stage 3 to Stage 2, 28.6%:19.5%). In contrast, the truncation ratio was increased in Stage 3 (Stage 3 to Stage 2, 71.4%:46.3%) ([Tables I and II](#t0005 t0010){ref-type="table"}).

The major lens proteins associated with Stage 4 were crystallin βB1 and βA4 ([Figure 3](#f0015){ref-type="fig"} and [Table II](#t0010){ref-type="table"}). Sixteen proteins were identified as crystallin βB1. Of these, 4 were phosphorylated, and none was acetylated or truncated. In addition, 9 proteins were identified as crystallin βA4, none of which was modified or truncated. The ratio of phosphorylated to nonphosphorylated proteins in Stage 4 was 4:21. The prevalence of modifications such as phosphorylation (16%), acetylation (0%), and truncation (0%) decreased in Stage 4 ([Tables I and II](#t0005 t0010){ref-type="table"}).

The major protein components associated with Stage 5 cataract lenses ([Figure 4](#f0020){ref-type="fig"} and [Tables I and II](#t0005 t0010){ref-type="table"}) were crystallin αA, βA4, and αB. Of these, 19 proteins were identified as truncated crystallin αA, and 11 of them were phosphorylated. Fourteen proteins were identified as crystallin αB. Of these, 8 were phosphorylated, 4 were acetylated, and none was truncated. Six proteins were identified as crystallin βA4, 1 of which was phosphorylated, and none was acetylated or truncated. In Stage 5, the ratio of phosphorylated to nonphosphorylated proteins was 20:19, that of acetylated to nonacetylated proteins was 4:35, and that of truncated to nontruncated proteins was 19:20. The prevalence of phosphorylation (51.3%) and truncation (48.7%) increased again in Stage 5, whereas that of acetylated crystallin proteins (10.3%) remained low ([Table II](#t0010){ref-type="table"}).

Discussion {#s0045}
==========

Cataract and intraocular lens surgery is progressing at an astonishing speed.[@bib19; @bib20] Nevertheless, cataracts are still the leading cause of blindness worldwide,[@bib4; @bib5; @bib13] especially in underdeveloped countries where cataract surgery is not widely available.[@bib15] Where it is available, cataract surgery continues to be expensive, representing a significant cost to health services in many nations.[@bib21] The etiology of cataracts involves induction of free radicals and superoxide-mediated damage to lens proteins by ultraviolet (UV) light.[@bib22; @bib23] The mechanisms of this disease remain elusive, and preventative medicines have not yet been discovered.[@bib20] In this study, we used proteomic analyses to determine differential expression and post-translational modifications of lens proteins during the development of cataracts.

Crystallins were identified as the most differentially expressed proteins in cataract lenses. The pI of human lens proteins was distributed from 5 to 9, and the molecular weight was between 10 and 120 kDa. Phosphorylation and truncation were increased in the early stages of lens clouding, indicating that these modifications of crystallins might contribute to the formation of cataracts.[@bib24; @bib25; @bib26; @bib27] Acetylation of crystallins was not as marked as phosphorylation in the opaque lens, although acetylation increased with the progression of cataracts. In contrast, phosphorylation, truncation, and acetylation decreased in Stage 4. This might indicate that the modification of crystallin proteins is not important in maintaining lens opacity in late-stage cataracts. In addition, microscopic structures of lenses begin to deteriorate in Stage 4; however, modification and truncation of crystallin proteins were not predominant in this stage. The major components of human lens crystallin were αA, βB1, αB, and βA4. The abundance of crystallin βA4 did not change with the progression of cataracts, and it remained the major component in every stage. Crystallin βB1 was also a dominant component in Stages 2 to 4 human cataract lenses; however, it disappeared in Stage 5 cataracts. These data suggested that crystallin βB1 is important in the progression of lens opacity in early and middle stages. Nevertheless, in severely opaque lenses, such as those in Stage 5, the basic structure had deteriorated to that of severe cataracts, such as morgagnian cataracts, and crystallin βB1 was totally absent. Crystallin αA was predominantly expressed in Stages 2, 3, and 5; however, it was not present in Stage 4. Therefore, crystallin αA might be involved in very early stages of cataract formation and later stages of severely opaque lenses. Very similar αB expression was noted in Stages 2 and 5.[@bib28; @bib29; @bib30; @bib31; @bib32]

[n]{.smallcaps}-acetylcarnosine or carcinine eye drops resistant to enzymatic hydrolysis could act as pharmacological chaperones and decrease oxidative stress and excessive glycation in stress-related eyes such as cataracts. Ischemic diabetic retinopathy might protect against nuclear sclerotic cataracts, and these findings were consistent with the hypothesis that increased exposure to oxygen is responsible for nuclear cataract formation.[@bib33] None of the patients in this study used these drugs regularly, but the relations of these drugs' antioxidative function and the crystalline changes noted in this study are worthy of advanced studies.[@bib34] In contrast, 2 well-known drugs, corticosteroids[@bib35] and the antipsychotic drug quetiapine,[@bib36] can induce cataracts; none of our patients received these drugs for \>1 month; therefore, they were not the issues of our study. Cataracts are also classified by their location, with the posterior type usually due to steroid and diabetes mellitus.[@bib35; @bib37] To decrease the special cataract type--induced bias in the study, the score of LOCS classification focus in any part, and the difference of any 2 parts over 4 (denoted as 0 and 4 by the 2 parts), were excluded from this study. To study the crystalline expression of different cataracts is also an important issue and worthy of study in the future. Other special type cataracts, such as traumatic cataracts, congenital cataracts, and exfoliation syndrome, were excluded in this study to obtain the simple information of natural progressing cataracts. In conclusion, crystallin protein levels and post-translational modifications were changeable during the progression of cataracts.

Conclusions {#s0050}
===========

Crystallin protein levels and post-translational modifications were changeable during the progression of cataracts. Understanding these protein dynamics during the formation of cataracts might help in designing distinct treatments for this disease.
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![Spots 1 to 44 existed in Stage 2 cataracts. MW, molecular weight.](gr1){#f0005}

![Spots 45 to 91 existed in Stage 3 cataracts. MW, molecular weight.](gr2){#f0010}

![Spots 92 to 129 existed in Stage 4 cataracts. MW, molecular weight.](gr3){#f0015}

![Spots 130 to 175 existed in Stage 5 cataracts. MW, molecular weight.](gr4){#f0020}

###### 

Proteins identified from mass spectrometry.

  Spot No.   Accession No.   Protein Identification       MW (kDa) /pI   Score   Post-translational Modification
  ---------- --------------- ---------------------------- -------------- ------- ---------------------------------
  1          P02489          α-Crystallin A chain         19.9/5.77      448     Ac Pi
  2          P02489          α-Crystallin A chain         19.9/5.77      464     Ac Pi
  3          P02489          α-Crystallin A chain         19.9/5.77      511     Ac Pi
  4          P02489          α-Crystallin A chain         19.9/5.77      375     Pi
  5          P02489          α-Crystallin A chain         19.9/5.77      561     Ac Pi
  6          P02489          α-Crystallin A chain         19.9/5.77      642     Ac Pi
  7          P02489          α-Crystallin A chain         19.9/5.77      383     Pi
  8          P02489          α-Crystallin A chain         19.9/5.77      365     Ac
  9          P53673          β-Crystallin A4              22.2/5.82      526     Pi
  10         P53673          β-Crystallin A4              22.2/5.82      407     Pi
  11         P53673          β-Crystallin A4              22.2/5.82      510     
  12         P53673          β-Crystallin A4              22.2/5.82      546     Pi
  13         P02489          α-Crystallin A chain         19.9/5.77      475     
  14         P53673          β-Crystallin A4              22.2/5.82      413     
  15         P53674          β-Crystallin B1              27.9/8.59      1068    Pi
  16         P05813          β-Crystallin A3              25.1/5.81      665     Ac Pi
  17         P53673          β-Crystallin A4              22.2/5.82      541     
  18         P07320          γ-Crystallin D               20.6/7.15      519     
  19         P53674          β-Crystallin B1              27.9/8.59      1077    Ac Pi
  20         P53674          β-Crystallin B1              27.9/8.59      928     
  21         P53674          β-Crystallin B1              27.9/8.59      1177    Pi
  22         P53674          β-Crystallin B1              27.9/8.59      1145    
  23         P53674          β-Crystallin B1              27.9/8.59      1073    
  24         P53674          β-Crystallin B1              27.9/8.59      1215    Pi
  25         P53674          β-Crystallin B1              27.9/8.59      1135    Pi
  26         P53674          β-Crystallin B1              27.9/8.59      1081    Pi
  27         P53674          β-Crystallin B1              27.9/8.59      932     
  28         P53674          β-Crystallin B1              27.9/8.59      926     
  29         P43320          β-Crystallin B2              23.2/6.54      679     
  30         P07315          γ-Crystallin C               20.7/7.04      650     
  31         P07320          γ-Crystallin D               20.6/7.15      450     
  32         P07315          γ-Crystallin C               20.7/7.04      665     
  33         P02511          α-Crystallin B chain         20.1/6.76      515     
  34         P02511          α-Crystallin B chain         20.1/6.76      607     Pi
  35         P02511          α-Crystallin B chain         20.1/6.76      591     Pi
  36         P02511          α-Crystallin B chain         20.1/6.76      694     Pi
  37         P02511          α-Crystallin B chain         20.1/6.76      565     
  38         P02511          α-Crystallin B chain         20.1/6.76      407     
  39         P02511          α-Crystallin B chain         20.1/6.76      338     
  40         P02489          α-Crystallin A chain         19.9/5.77      409     Ac
  41         Q01469          Fatty acid-binding protein   15.0/6.84      207     
  42         P02489          α-Crystallin A chain         19.9/5.77      441     
  43         P02489          α-Crystallin A chain         19.9/5.77      309     
  44         P02489          α-Crystallin A chain         19.9/5.77      402     
  45         P02489          α-Crystallin A chain         19.9/5.77      354     Ac Pi
  46         P02489          α-Crystallin A chain         19.9/5.77      481     Ac Pi
  47         P02489          α-Crystallin A chain         19.9/5.77      557     Ac Pi
  48         P02489          α-Crystallin A chain         19.9/5.77      661     Ac Pi
  49         P22914          β-Crystallin S               20.9/6.43      515     Ac Pi
  50         P53674          β-Crystallin B1              27.9/8.59      586     
  51         P02489          α-Crystallin A chain         19.9/5.77      597     Ac Pi
  52         P02489          α-Crystallin A chain         19.9/5.77      564     Ac Pi
  53         P05813          β-Crystallin A3              25.1/5.81      569     Pi
  54         P05813          β-Crystallin A3              25.1/5.81      708     Ac Pi
  55         P53674          β-Crystallin B1              27.9/8.59      1105    Ac Pi
  56         P05813          β-Crystallin A3              25.1/5.81      753     Pi
  57         P53674          β-Crystallin B1              27.9/8.59      1051    Ac Pi
  58         P05813          β-Crystallin A3              25.1/5.81      688     Pi
  59         P05813          β-Crystallin A3              25.1/5.81      847     Pi
  60         P02511          α-Crystallin B chain         20.1/6.76      595     Pi
  61         P43320          β-Crystallin B2              23.2/6.54      437     Ac Pi
  62         P53674          β-Crystallin B1              27.9/8.59      1033    Pi
  63         P53674          β-Crystallin B1              27.9/8.59      637     
  64         P53674          β-Crystallin B1              27.9/8.59      1022    Pi
  65         P53674          β-Crystallin B1              27.9/8.59      1082    Pi
  66         P43320          β-Crystallin B2              23.2/6.54      703     
  67         P05813          β-Crystallin A3              25.1/5.81      640     
  68         P53674          β-Crystallin B1              27.9/8.59      1058    Pi
  69         P53674          β-Crystallin B1              27.9/8.59      1366    Pi
  70         P02511          α-Crystallin B chain         20.1/6.76      791     
  71         P02511          α-Crystallin B chain         20.1/6.76      497     
  72         P02511          α-Crystallin B chain         20.1/6.76      510     
  73         P02511          α-Crystallin B chain         20.1/6.76      466     Pi
  74         P05813          β-Crystallin A3              25.1/5.81      427     
  75         P07320          γ-Crystallin D               20.6/7.15      216     
  76         P02511          α-Crystallin B chain         20.1/6.76      239     
  77         P02489          α-Crystallin A chain         19.9/5.77      373     
  78         P53673          β-Crystallin A4              22.2/5.82      484     
  79         P02489          α-Crystallin A chain         19.9/5.77      511     Ac Pi
  80         P53673          β-Crystallin A4              22.2/5.82      442     
  81         P53673          β-Crystallin A4              22.2/5.82      523     
  82         P53673          β-Crystallin A4              22.2/5.82      478     
  83         P53673          β-Crystallin A4              22.2/5.82      436     
  84         P53673          β-Crystallin A4              22.2/5.82      362     
  86         P02489          α-Crystallin A chain         19.9/5.77      364     Ac
  87         P02489          α-Crystallin A chain         19.9/5.77      309     
  88         P02489          α-Crystallin A chain         19.9/5.77      278     
  89         P02489          α-Crystallin A chain         19.9/5.77      201     
  90         P02489          α-Crystallin A chain         19.9/5.77      234     
  91         P02489          α-Crystallin A chain         19.9/5.77      247     
  92         P02489          α-Crystallin A chain         19.9/5.77      135     
  93         P53674          β-Crystallin B1              27.9/8.59      155     
  94         P53674          β-Crystallin B1              27.9/8.59      432     
  95         P53674          β-Crystallin B1              27.9/8.59      718     
  96         P53674          β-Crystallin B1              27.9/8.59      337     
  97         P53674          β-Crystallin B1              27.9/8.59      945     
  98         P53674          β-Crystallin B1              27.9/8.59      889     
  99         P53674          β-Crystallin B1              27.9/8.59      1009    
  100        P05813          β-Crystallin A3              25.1/5.81      691     
  101        P05813          β-Crystallin A3              25.1/5.81      551     Ac Pi
  102        P53674          β-Crystallin B1              27.9/8.59      1071    Pi
  103        P53674          β-Crystallin B1              27.9/8.59      1029    
  104        P05813          β-Crystallin A3              25.1/5.81      608     
  105        P53674          β-Crystallin B1              27.9/8.59      1214    Pi
  106        P05813          β-Crystallin A3              25.1/5.81      621     
  107        P53674          β-Crystallin B1              27.9/8.59      786     
  108        P53674          β-Crystallin B1              27.9/8.59      997     Pi
  109        P53674          β-Crystallin B1              27.9/8.59      923     
  110        P53674          β-Crystallin B1              27.9/8.59      1161    Pi
  111        P53674          β-Crystallin B1              27.9/8.59      927     
  112        P53674          β-Crystallin B1              27.9/8.59      876     
  113        P05813          β-Crystallin A3              25.1/5.81      551     
  114        P05813          β-Crystallin A3              25.1/5.81      475     
  115        P07315          γ-Crystallin C               20.7/7.04      465     
  116        P02511          α-Crystallin B chain         20.1/6.76      170     
  117        P02511          α-Crystallin B chain         20.1/6.76      239     
  118        P02489          α-Crystallin A chain         19.9/5.77      206     
  119        P53673          β-Crystallin A4              22.2/5.82      192     
  120        P53673          β-Crystallin A4              22.2/5.82      447     
  121        P53673          β-Crystallin A4              22.2/5.82      539     
  122        P02489          α-Crystallin A chain         19.9/5.77      296     
  123        P53673          β-Crystallin A4              22.2/5.82      424     
  124        P53673          β-Crystallin A4              22.2/5.82      475     
  125        P53673          β-Crystallin A4              22.2/5.82      481     
  126        P53673          β-Crystallin A4              22.2/5.82      444     
  127        P53673          β-Crystallin A4              22.2/5.82      512     
  128        P53673          β-Crystallin A4              22.2/5.82      396     
  129        P02489          α-Crystallin A chain         19.9/5.77      485     
  130        P53673          β-Crystallin A4              22.2/5.82      402     
  131        P02489          α-Crystallin A chain         19.9/5.77      513     Ac Pi
  132        P02489          α-Crystallin A chain         19.9/5.77      494     Ac Pi
  133        P02489          α-Crystallin A chain         19.9/5.77      641     Ac Pi
  134        P02489          α-Crystallin A chain         19.9/5.77      707     Ac Pi
  135        P02489          α-Crystallin A chain         19.9/5.77      506     Ac Pi
  136        P53673          β-Crystallin A4              22.2/5.82      517     
  137        P53673          β-Crystallin A4              22.2/5.82      570     
  138        P02489          α-Crystallin A chain         19.9/5.77      579     Ac Pi
  139        P53673          β-Crystallin A4              22.2/5.82      553     Pi
  140        P02489          α-Crystallin A chain         19.9/5.77      460     Ac Pi
  141        P02489          α-Crystallin A chain         19.9/5.77      409     Ac Pi
  142        P02489          α-Crystallin A chain         19.9/5.77      329     
  143        P02489          α-Crystallin A chain         19.9/5.77      553     
  144        P02489          α-Crystallin A chain         19.9/5.77      755     Ac Pi
  145        P02489          α-Crystallin A chain         19.9/5.77      641     Pi
  146        P53673          β-Crystallin A4              22.2/5.82      372     
  147        P02489          α-Crystallin A chain         19.9/5.77      308     
  149        P53673          β-Crystallin A4              22.2/5.82      405     
  150        P02489          α-Crystallin A chain         19.9/5.77      439     Pi
  151        P07320          γ-Crystallin D               20.6/7.15      458     
  152        P02511          α-Crystallin B chain         20.1/6.76      775     PiAc
  153        P07320          γ-Crystallin D               20.6/7.15      445     
  154        P02511          α-Crystallin B chain         20.1/6.76      882     Pi
  155        P02511          α-Crystallin B chain         20.1/6.76      948     PiAc
  156        P43320          β-Crystallin B2              23.2/6.54      1292    Ac
  157        P43320          β-Crystallin B2              23.2/6.54      1346    PiAc
  158        P02511          α-Crystallin B chain         20.1/6.76      693     
  159        P02511          α-Crystallin B chain         20.1/6.76      489     
  160        P02511          α-Crystallin B chain         20.1/6.76      895     PiAc
  161        P02511          α-Crystallin B chain         20.1/6.76      982     PiAc
  162        P02511          α-Crystallin B chain         20.1/6.76      964     Pi
  163        P02511          α-Crystallin B chain         20.1/6.76      268     
  164        P02511          α-Crystallin B chain         20.1/6.76      228     Pi
  166        P02511          α-Crystallin B chain         20.1/6.76      758     
  167        P02511          α-Crystallin B chain         20.1/6.76      821     Pi
  169        P02511          α-Crystallin B chain         20.1/6.76      282     
  170        P02511          α-Crystallin B chain         20.1/6.76      307     
  171        P02489          α-Crystallin A chain         19.9/5.77      314     
  172        P02489          α-Crystallin A chain         19.9/5.77      255     Ac
  173        P02489          α-Crystallin A chain         19.9/5.77      284     
  175        P02489          α-Crystallin A chain         19.9/5.77      143     

Ac, acetylation; MW, molecular weight; Pi, phosphorylation; PiAc, phosphorylation, acetylation; pI, isoelectric point.

###### 

The proteins expressed in cataracts.

  Stage   Total Protein Number   Proteins (no.)   Phosphorylation (%)   Acetylation (%)   Truncation (%)                                       
  ------- ---------------------- ---------------- --------------------- ----------------- ---------------- ----------- ----------- ----------- -----------
  2       44                     βB1 11           αB 11                 αA 11             βA4 8            Others 3    19 (46.3)   8 (19.5)    19 (46.3)
  3       47                     αA 13            βB1 10                βA3 6             βA4 6            Others 12   19 (54.3)   10 (28.6)   25 (71.4)
  4       38                     βB1 16           βA4 9                                                    Others 13   4 (16)      0           0
  5       46                     αA 19            βA4 14                αB 6                               Others 7    20 (51.3)   4 (10.3)    19 (48.7)

[^1]: These authors contributed equally to this work.
